CN114028399A - Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma - Google Patents
Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma Download PDFInfo
- Publication number
- CN114028399A CN114028399A CN202111549537.XA CN202111549537A CN114028399A CN 114028399 A CN114028399 A CN 114028399A CN 202111549537 A CN202111549537 A CN 202111549537A CN 114028399 A CN114028399 A CN 114028399A
- Authority
- CN
- China
- Prior art keywords
- ipp
- glioma
- cells
- mif inhibitor
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZTCJXHNJVLUUMR-UHFFFAOYSA-N 4-iodo-6-phenylpyrimidine Chemical compound C1=NC(I)=CC(C=2C=CC=CC=2)=N1 ZTCJXHNJVLUUMR-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 239000003112 inhibitor Substances 0.000 title claims abstract description 12
- 201000007983 brain glioma Diseases 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title description 7
- 206010018338 Glioma Diseases 0.000 claims abstract description 25
- 208000032612 Glial tumor Diseases 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 210000004027 cell Anatomy 0.000 claims description 28
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 238000007920 subcutaneous administration Methods 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 2
- 238000002054 transplantation Methods 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 20
- 108010087230 Sincalide Proteins 0.000 description 8
- 238000010609 cell counting kit-8 assay Methods 0.000 description 8
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of an MIF inhibitor 4-IPP in preparing a medicament for treating brain glioma. The invention establishes that the MIF inhibitor 4-IPP can inhibit the proliferation, clone formation and transfer capability of glioma cells, and simultaneously the micromolecule compound can inhibit the growth of subcutaneous ectopic transplantation tumors and has the effect of treating glioma. The micromolecule compound has application value in glioma treatment according to the tumor inhibition effect of the micromolecule compound on glioma.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of an MIF inhibitor 4-IPP in preparation of a medicine for treating brain glioma.
Background
Brain Gliomas (Gliomas) are the most common primary malignancies of the central nervous system, with invasive growth, high recurrence, poor prognosis, and are one of the most challenging diseases in cancer treatment [1 ]. The annual incidence rate of the glioma is about 6/10 ten thousand, and the average survival rate in 5 years is lower than 10% [2 ]; glioblastoma (glioblastomas) are WHO grade iv gliomas with extremely high malignancy, with an average time from diagnosis to death of less than 18 months [3 ].
Currently, surgical resection, chemotherapy in combination with radiotherapy and targeted immunotherapy are the main approaches to the treatment of glioma. However, the mean survival time of glioma patients has not been substantially improved due to postoperative tumor residues, decreased sensitivity to radiation therapy, chemotherapy resistance, and the like. Macrophage Migration Inhibitory Factor (MIF) is a pluripotent cytokine with properties of enzymes, chemokines, hormones and the like [4], and MIF directly participates in the regulation of tumor cells to promote tumor growth, metastasis and angiogenesis [5 ]. The research shows that MIF is highly expressed in a plurality of tumors such as prostate cancer, pancreatic cancer, melanoma, colon cancer, glioma and the like [6-10 ]. RT-PCR quantitatively detected that MIF mRNA expression in malignant glioma cells was 800-fold higher than in normal brain tissue and this was associated with high levels of total cell lysate and secreted MIF protein [11 ]. It has also been found that overexpression of MIF induces angiogenesis, associated with stage and metastatic spread of glioma [4-5 ]; elevated MIF expression is also associated with tumor recurrence and poor prognosis in patients with glioblastoma [12 ]. Thus, MIF may be a novel target for glioma therapy.
Disclosure of Invention
The invention aims to provide an application of an MIF inhibitor 4-iodo-6-phenylpyrimidine (4-IPP) in preparation of a glioma treatment drug for preparation of a glioma treatment drug.
The second purpose of the invention is to provide an application of MIF inhibitor 4-IPP in preparing glioma cell proliferation inhibition drugs.
The third purpose of the invention is to provide an application of MIF inhibitor 4-IPP in preparing a brain glioma cell metastasis inhibition drug.
Compared with the prior art, the invention has the following beneficial effects:
the invention discloses the application of MIF inhibitor 4-IPP in preparing a medicament for treating brain glioma for the first time, wherein in vitro experiments are carried out to treat U87 and U251 glioma cells by adopting 4-IPP with different concentrations, and CCK-8 and clone formation experiments are used for detecting the proliferation capacity and clone formation capacity of U87 and U251 glioma cells after 4-IPP treatment; the inhibition of U87 and U251 cell Migration/Invasion by 4-IPP was examined by Migration/Invasion experiments using a Transwell chamber. Further in vivo experiments, a male nude mouse subcutaneous xenograft tumor model is constructed by U87, the treatment effect of MIF inhibitor 4-IPP on glioma is observed by injecting PBS group (Control group) and 20mg/kg 4-IPP group (treatment group) into nude mice intraperitoneally, the tumor size is calculated, the tumor mass is weighed, and the tumor volume is calculated. Research results show that 4-IPP can effectively inhibit glioma cell proliferation, clone formation and metastasis and treat glioma.
Drawings
FIG. 1 is a graph showing the effect of the experiment on proliferation of CCK-8 of U87 cells treated with 4-IPP of example 1;
FIG. 2 is a graph showing the effect of the experiment on proliferation of CCK-8 in U251 cells treated with 4-IPP of example 1;
FIG. 3 is a graph showing the effect of the 4-IPP treatment of U87 and U251 cells in the cell clonogenic assay of example 1;
FIG. 4 is a graph showing the effect of the 4-IPP treatment of U87 and U251 cells in the Migration experiment and Invasion experiment of example 2;
FIG. 5 is a graph showing the effect of the subcutaneous xenograft tumor models in the PBS group and the 20mg/kg 4-IPP group of example 3;
Detailed Description
The specific experimental methods and results are as follows:
example 1
The first experiment method comprises the following steps:
1. cell proliferation assay CCK-8:
a generation of U87 and U251 cells was seeded at 2000 cells/well in a 96-well plate, and 4-IPP solutions at concentrations of 0.390625. mu.M, 0.78125. mu.M, 1.5625. mu.M, 3.125. mu.M, 6.25. mu.M, 12.5. mu.M, 25. mu.M, 50. mu.M, 100. mu.M and 200. mu.M were added after 12 hours, respectively. After 24 hours of culture, 20. mu.L of CCK-8 kit was added and incubated at 37 ℃ for 2 hours, and then OD value was measured with a fluorescence microplate reader.
2. Clone formation experiments:
taking monolayer cultured cells in logarithmic phase, digesting with pancreatin, blowing into single cells, counting the cells after resuspension, paving the cells into a six-hole plate according to the density of 200 cells/hole, shaking the plate to disperse the cells, and placing the cells in an incubator overnight. The following day, 12.5. mu.M, 25. mu.M and 50. mu.M of 4-IPP were added, and the solution was changed 2 times per week for 2-3 weeks. The culture was terminated when macroscopic colonies appeared in the culture dish, observed every other day. The supernatant was discarded, fixed and stained with crystal violet, and the clones were counted directly with the naked eye or the number of clones larger than 10 cells was counted under a microscope (low power mirror).
II, experimental results:
FIG. 1 shows that 4-IPP can significantly inhibit the proliferation capacity of U87 by detecting the proliferation of U87 cells by using a CCK-8 reagent after the U87 cells are treated for 24 hours in vitro by setting a concentration gradient of 4-IPP. FIG. 2 shows that after U251 cells are treated for 24h by setting concentration gradient 4-IPP in vitro, the cell proliferation condition is detected by using CCK-8 reagent, and the result shows that the 4-IPP can obviously inhibit the proliferation capacity of U251. Based on the results obtained from the CCK-8 experiment, further cloning experiments were performed using concentration gradients, and the results in FIG. 3 show that 4-IPP can effectively inhibit the clonogenic capacity of U87/U251. The above results indicate that 4-IPP can effectively inhibit the proliferation and clonogenic capacity of glioma cell U87/U251.
Example 2
The first experiment method comprises the following steps:
1. migration and Invasion experiments:
transwell cells (24-well plates) were used for the Migration experiments and the matrigel-coated Invasion experiments. For the Migration experiment, 200ul of cell suspension (density 2X 10) was taken5) Transwell chambers were added and 500. mu.l of complete medium containing different concentrations of 4-IPP was placed in the lower chamber and samples were collected after 24 hours of culture. For the invasion assay, 200ul of cell suspension (density 2X 10) was placed after Matrigel coating the upper chamber5) At the same time, 500. mu.l of complete medium containing 4-IPP at various concentrations was added to the lower chamber and the samples were collected after 24 hours of culture. After the sample is collected, the crystal violet is stained, and a picture is taken by a microscope.
II, experimental results:
FIG. 4 shows the validation of the inhibitory effect of MIF inhibitor 4-IPP on U87 and U251 cell Migration by Migration and Invasion experiments in vitro using Transwell chambers; the results show that 4-IPP treatment can significantly reduce the number of U87/U251 cell metastases; further laying Matrigel to simulate the matrix environment for Invasion experiments, the 4-IPP treatment also significantly reduced the number of U87/U251 cells invading the lower part of the chamber through the matrix.
Example 3
The first experiment method comprises the following steps:
1. establishment of a male nude mouse subcutaneous ectopic transplantation tumor model:
male nude mice for 4 weeks were housed in an SPF-rated animal house with 5 mice per cage, and given sufficient food and water with appropriate temperature, humidity and light cycle control. Make a total of 5107One U87 stable cell was injected into the lower right dorsal side (each group n-5).
2. Grouping: after one week, we randomly divided the mice into two groups. The PBS group and the 20mg/kg 4-IPP group were injected intraperitoneally, respectively. After 3 weeks of injection every other day, mice were euthanized and tumors were removed and photographed.
3. Preparation of injection: 4-IPP was first dissolved in DMSO, and then the DMSO stock solution was dissolved in PBS for preparation of 4-IPP injections at different concentrations.
II, experimental results:
FIG. 5 is a graph showing the effect of the subcutaneous xenograft tumor models in PBS and 20mg/kg 4-IPP groups. As can be seen, compared with the Control group, the glioma tissue volume and weight of the 4-IPP group with 20mg/kg are obviously reduced, which indicates that the 4-IPP can effectively inhibit the growth of glioma cells in vivo and has the function of treating brain glioma.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
The references referred to in this specification are as follows:
[1]Lapointe S,Perry A,Butowski NA.Primary brain tumours in adults.Lancet,2018,392(10145):432-446.
[2]Hiroko Ohgaki,Paul Kleihues.Population-based studies on incidence,survivalrates,and genetic alterations in astrocytic and oligodendroglial gliomas.JNeuropathol Exp Neurol,2005,64(6):479-489.
[3]Stupp R,Hegi ME,Mason WP,et al.Effects of radiotherapy with concomitantand adjuvant temozolomide versus radiotherapy alone on survival in glioblastomain a randomised phase III study:5-year analysis of the EORTC-NCIC trial.Lancet Oncol,2009,10(5):459–466.
[4]Bach JP,Deuster O,Balzer-Geldsetzer M,et al.The Role of MacrophageInhibitory Factor in Tumorigenesis and Central Nervous System Tumors.Cancer,2009,115(10):2031-2040.
[5]Beatriz E Rendon,Sharon S Willer,Wayne Zundel,et al.Mechanisms ofmacrophage migration inhibitory factor(MIF)-dependent tumormicroenvironmental adaptation.Experimental and Molecular Pathology,2009,86(3):180-185.
[6]Hussain F,Freissmuth M,D,et al.Human anti-macrophage migrationinhibitory factor antibodies inhibit growth of human prostate cancer cells in vitroand in vivo.Mol Cancer Ther,2013,12(7):1223-1234.
[7]Shouhui Yang,Peijun He,Jian Wang,et al.ANovel MIF Signaling PathwayDrives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.Cancer Res,2016,76(13):3838-3850.
[8]Masako Imaoka,Keiji Tanese,Yohei Masugi,et al.Macrophage migrationinhibitory factor-CD74 interaction regulates the expression of programmed celldeath ligand 1 in melanoma cells.Cancer Sci,2019,110(7):2273-2283.
[9]Shugang Xu,Xing Guo,Xiao Gao,et al.Macrophage migration inhibitoryfactor enhances autophagy by regulating ROCK1 activity and contributes to theescape of dendritic cell surveillance in glioblastoma.Int J Oncol,2016,49(5):2105-2115.
[10]Wendy Ha,Hatice Sevim-Nalkiran,Ashraf M Zaman,et al.Ibudilast sensitizesglioblastoma to temozolomide by targeting Macrophage Migration InhibitoryFactor(MIF).Sci Rep,2019,9(1):2905.
[11]Mittelbronn M,Platten M,Zeiner P,et al.Macrophage migration inhibitory factor(MIF)expression in human malignant gliomas contributes to immune escape andtumour progression.Acta Neuropathol,2011,122(3):353-65.
[12]Xiao-Bing Wang,Xiao-Ying Tian,Yang Li,et al.Elevated expression ofmacrophage migration inhibitory factor correlates with tumor recurrence and poorprognosis of patients with gliomas.J Neurooncol,2012,106(1):43-51.
Claims (3)
2. Use of the small molecule compound 4-IPP of claim 1 in the manufacture of a medicament for inhibiting glioma cell proliferation.
3. Use of the small molecule compound 4-IPP of claim 1 in the manufacture of a medicament for inhibiting glioma cell metastasis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111549537.XA CN114028399A (en) | 2021-12-18 | 2021-12-18 | Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111549537.XA CN114028399A (en) | 2021-12-18 | 2021-12-18 | Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114028399A true CN114028399A (en) | 2022-02-11 |
Family
ID=80147005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111549537.XA Pending CN114028399A (en) | 2021-12-18 | 2021-12-18 | Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114028399A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186833A (en) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | MIF modulators |
CN103360399A (en) * | 2013-08-02 | 2013-10-23 | 北京大学 | 6-aryl-substituted-imidazole-[1,2-b]pyridazine derivative and preparation method and application thereof |
US20170144983A1 (en) * | 2014-03-28 | 2017-05-25 | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy | 3-Phenyl-7-Hydroxy-Isocoumarins as Macrophage Migration Inhibitory Factor (MIF) Inhibitors |
EP3428647A1 (en) * | 2017-07-12 | 2019-01-16 | Consejo Superior de Investigaciones Científicas (CSIC) | Expression signature for glioma diagnosis and/or prognosis in a subject |
-
2021
- 2021-12-18 CN CN202111549537.XA patent/CN114028399A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186833A (en) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | MIF modulators |
CN103360399A (en) * | 2013-08-02 | 2013-10-23 | 北京大学 | 6-aryl-substituted-imidazole-[1,2-b]pyridazine derivative and preparation method and application thereof |
US20170144983A1 (en) * | 2014-03-28 | 2017-05-25 | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy | 3-Phenyl-7-Hydroxy-Isocoumarins as Macrophage Migration Inhibitory Factor (MIF) Inhibitors |
EP3428647A1 (en) * | 2017-07-12 | 2019-01-16 | Consejo Superior de Investigaciones Científicas (CSIC) | Expression signature for glioma diagnosis and/or prognosis in a subject |
Non-Patent Citations (2)
Title |
---|
LEE SH,等: "Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP downregulates stemness phenotype and mesenchymal trans-differentiation after irradiation in glioblastoma multiforme", PLOS ONE, vol. 16, no. 9, pages 1 - 15 * |
赵炜熠;初明;: "胶质瘤免疫抑制与治疗的研究进展", 中国临床神经外科杂志, no. 03, pages 73 - 75 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106591306B (en) | Application of the siRNA of targeting interference tumour PTN-PTPRZ1 access in immunotherapy of tumors | |
Roy et al. | Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma | |
Cheng et al. | PKCα in colon cancer cells promotes M1 macrophage polarization via MKK3/6‐P38 MAPK pathway | |
CN109420170A (en) | Novel tumor microenvironment related target TAK1 and its application in inhibition tumour | |
Xia et al. | BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma | |
Luo et al. | Melatonin inhibits EMT and PD‐L1 expression through the ERK1/2/FOSL1 pathway and regulates anti‐tumor immunity in HNSCC | |
Wang et al. | The combinatorial effect of cisplatin and moxibustion on tumor growth inhibition with special reference to modulation of the immune microenvironment in Lewis lung cancer mice | |
Albanese et al. | Anti‐tumour efficacy on glioma models of PHA‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier | |
Geng et al. | Synthetic lethal short hairpin RNA screening reveals that ring finger protein 183 confers resistance to trametinib in colorectal cancer cells | |
Choi et al. | Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer | |
Yang et al. | Xanthatin selectively targets retinoblastoma by inhibiting the PLK1-mediated cell cycle | |
Lu et al. | Continuous low-dose-rate irradiation of iodine-125 seeds inhibiting perineural invasion in pancreatic cancer | |
Fang et al. | Targeting strategies for renal cancer stem cell therapy | |
Cheng et al. | HDAC1 mediates epithelial–mesenchymal transition and promotes cancer cell invasion in glioblastoma | |
Sokolov et al. | Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics | |
CN105497896A (en) | Tumor drug-resistant target and application thereof | |
CN114028399A (en) | Application of MIF inhibitor 4-IPP in preparation of medicine for treating brain glioma | |
Suzuki et al. | Overexpression of TEAD4 in atypical teratoid/rhabdoid tumor: new insight to the pathophysiology of an aggressive brain tumor | |
CN101954077B (en) | Expression plasmid adjuvant for enhancing chemotherapeutic effect of tumor chemotherapeutics and preparation method thereof | |
CN113855663A (en) | Application of oridonin in preparation of anti-prostatic cancer drugs | |
Wang et al. | Human serum albumin-bound paclitaxel nanoparticle inhibits cervical carcinoma cell proliferation and oxidative damage through CYP3A4 and CYP2C8 | |
Zhang et al. | Cancer-associated fibroblasts-induced remodeling of tumor immune microenvironment via Jagged1 in glioma | |
Chen et al. | ADRB2 Regulates the Proliferation and Metastasis of Gastrointestinal Stromal Tumor Cells by Enhancing the ETV1‐c‐KIT Signaling | |
Burzynski et al. | Comprehensive genomic profiling of recurrent classic glioblastoma in a patient surviving eleven years following antineoplaston therapy | |
Tanrikulu et al. | In vitro effects of mesenchymal stem cells and various agents on apoptosis of glioblastoma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220211 |
|
WD01 | Invention patent application deemed withdrawn after publication |